Angiocrine Bioscience CEO and leadership

C. Geoffrey Davis was most recently President and Chief Scientific Officer of Angiocrine Bioscience. He was also a founder and the Chief Scientific Officer for Abgenix, Inc. in Fremont, California. He led the development of the XenoMouse technology, which provided the basis for Abgenix to grow from a Cell Genesys spinout and be acquired by Amgen. During this time, he advanced three antibody product candidates into clinical trials and was instrumental in identifying, structuring, and managing over 30 corporate partnerships. To date, these partnerships have resulted in 11 antibody product candidates derived from XenoMouse technology entering clinical trials and two being approved for the market. C. Geoffrey Davis received his Ph.D. from the University of California, San Francisco and completed his postdoctoral work in the laboratory of Nobel Laureates Joseph L. Goldstein and Michael S. Brown at The University of Texas, Southwestern. Prior to founding Abgenix, C. Geoffrey Davis was a faculty member at UCSF, an investigator with the Howard Hughes Medical Institute, and Director of Immunology at both Repligen Corporation and Cell Genesys, Inc. He also consults for several biotechnology/pharmaceutical companies and serves on the Board of Directors for four companies.

Dr Fraser is Chief Scientific Officer at Angiocrine Bioscience Inc, a San Diego biotechnology company developing novel cell therapies based on a proprietary allogeneic endothelial cell platform (E-CEL UVEC). He has over 30 years of experience working with adult stem cells in both academia and industry. During his career he has been Principal Investigator on several USA government research contracts and grants amounting to almost $50 million in awarded funding. These include ~USD$14 million in contracts and grants from the National Heart, Lung, and Blood Institute of the NIH and an ongoing contract valued at up to USD$106 million from the Biomedical Advanced Research and Development Authority (~$34MM allocated to date).

Prior to joining Angiocrine, Dr Fraser was Chief Scientist at Cytori Therapeutics Inc. Before joining Cytori he had a 12 year career in the Department of Medicine at UCLA. He was an Adjunct Associate Professor in the Division of Hematology-Oncology and a member of the Jonsson Comprehensive Cancer Center. For three years Dr Fraser was the Co-Director of the UCLA Bone Marrow Transplant Laboratory, the facility responsible for processing and cryopreservation of all bone marrow and peripheral blood stem cells used in marrow transplants at UCLA. He also founded and, from 1995 until he left to join Cytori, was the Director and Principal Investigator of the UCLA Umbilical Cord Blood Bank, a NIH-funded allogeneic cord blood stem cell bank. In addition, Dr Fraser was a member of one of UCLA’s two Medical Institutional Review Boards for seven years and served as Vice Chair of the Board for two years. He has served on five NIH panels reviewing stem cell-related research proposals.

Dr Fraser has a PhD from the University of Otago in New Zealand and a Bachelor of Science degree (Biochemistry and Physiology) from Victoria University of Wellington. He has published more than 50 peer-reviewed papers, has 35 patents issued in the USA and many more internationally.

C. Geoffrey Davis was most recently President and Chief Scientific Officer of Angiocrine Bioscience. He was also a founder and the Chief Scientific Officer for Abgenix, Inc. in Fremont, California. He led the development of the XenoMouse technology, which provided the basis for Abgenix to grow from a Cell Genesys spinout and be acquired by Amgen. During this time, he advanced three antibody product candidates into clinical trials and was instrumental in identifying, structuring, and managing over 30 corporate partnerships. To date, these partnerships have resulted in 11 antibody product candidates derived from XenoMouse technology entering clinical trials and two being approved for the market. C. Geoffrey Davis received his Ph.D. from the University of California, San Francisco and completed his postdoctoral work in the laboratory of Nobel Laureates Joseph L. Goldstein and Michael S. Brown at The University of Texas, Southwestern. Prior to founding Abgenix, C. Geoffrey Davis was a faculty member at UCSF, an investigator with the Howard Hughes Medical Institute, and Director of Immunology at both Repligen Corporation and Cell Genesys, Inc. He also consults for several biotechnology/pharmaceutical companies and serves on the Board of Directors for four companies.

Dr Fraser is Chief Scientific Officer at Angiocrine Bioscience Inc, a San Diego biotechnology company developing novel cell therapies based on a proprietary allogeneic endothelial cell platform (E-CEL UVEC). He has over 30 years of experience working with adult stem cells in both academia and industry. During his career he has been Principal Investigator on several USA government research contracts and grants amounting to almost $50 million in awarded funding. These include ~USD$14 million in contracts and grants from the National Heart, Lung, and Blood Institute of the NIH and an ongoing contract valued at up to USD$106 million from the Biomedical Advanced Research and Development Authority (~$34MM allocated to date).

Prior to joining Angiocrine, Dr Fraser was Chief Scientist at Cytori Therapeutics Inc. Before joining Cytori he had a 12 year career in the Department of Medicine at UCLA. He was an Adjunct Associate Professor in the Division of Hematology-Oncology and a member of the Jonsson Comprehensive Cancer Center. For three years Dr Fraser was the Co-Director of the UCLA Bone Marrow Transplant Laboratory, the facility responsible for processing and cryopreservation of all bone marrow and peripheral blood stem cells used in marrow transplants at UCLA. He also founded and, from 1995 until he left to join Cytori, was the Director and Principal Investigator of the UCLA Umbilical Cord Blood Bank, a NIH-funded allogeneic cord blood stem cell bank. In addition, Dr Fraser was a member of one of UCLA’s two Medical Institutional Review Boards for seven years and served as Vice Chair of the Board for two years. He has served on five NIH panels reviewing stem cell-related research proposals.

Dr Fraser has a PhD from the University of Otago in New Zealand and a Bachelor of Science degree (Biochemistry and Physiology) from Victoria University of Wellington. He has published more than 50 peer-reviewed papers, has 35 patents issued in the USA and many more internationally.